



Correct and help
protect their vision
from getting worse
as they grow.^{*†‡1,2}

MISIGHT® TODAY. ANYTHING TOMORROW.

Is your child struggling with distance vision?

Meet MiSight® 1 day, the FIRST and ONLY FDA-approved* soft contact lenses to slow the progression of myopia in children aged 8-12 at the initiation of treatment.^{§1}

Don't wait! Not only will MiSight® 1 day help your age-appropriate child see clearly,^{1,3,4} it can help protect their blurry vision from getting worse.^{*†§1,2}

Ask us today about MiSight® 1 day and how easy it is for you to positively impact your child's sight.



MiSight® 1 day
for daily wear

*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

†ActivControl® technology in MiSight® 1 day contact lenses slows axial length elongation and corrects refractive error for age-appropriate children.

‡MiSight® 1 day shows sustained slowing of eye growth over time on average. While eyes are still growing; children fit ages 8-12 and followed for 6-years. n=40.

§Compared to a single vision 1 day lens.

1. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
2. Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.
3. Sulley A et al, Wearer experience and subjective responses with dual focus compared to spherical, single vision soft contact lenses in children during a 3-year clinical trial. AAO 2019 Poster Presentation.
4. Chamberlain P et al, Further comparison of myopia progression in new and established myopia control treatment (MiSight® 1 day) groups. BCLA paper presentation 2019.